New chemo cocktail aims to shrink hard-to-treat childhood muscle cancer

NCT ID NCT05457829

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen May 19, 2026 · Last updated Jun 14, 2026 · Updated 4 times

Summary

This study compares two chemotherapy combinations in 88 children (ages 6 months to 18 years) whose rhabdomyosarcoma has returned or not responded to prior treatment. One group receives doxorubicin liposome plus irinotecan (AI regimen), the other receives the standard VIT regimen. The main goal is to see which combination shrinks tumors more after two cycles of treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHABDOMYOSARCOMA, CHILD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sun Yat-Sen University Cancer Center
RECRUITING

Guangzhou, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

rhabdomyosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHABDOMYOSARCOMA, CHILD